Literature DB >> 17018389

Human cell engraftment after busulfan or irradiation conditioning of NOD/SCID mice.

Elodie Robert-Richard1, Cécile Ged, Jacqueline Ortet, Xavier Santarelli, Isabelle Lamrissi-Garcia, Hubert de Verneuil, Frédéric Mazurier.   

Abstract

Human hematopoietic stem cell (HSC) xenotransplantation in NOD/SCID mice requires recipient conditioning, classically achieved by sublethal irradiation. Pretreatment with immunosuppressive and alkylating agents has been reported, but has not been rigorously tested against standard irradiation protocols. Here, we report that treatment of mice with a single dose (35 mg/kg) of Busilvex, an injectable form of busulfan, enables equivalent engraftment compared to 3.5 Gy irradiation. Mice treated with two doses of 25 mg/kg to reduce busulfan toxicity showed increased chimerism. Busulfan conditioning and irradiation resulted in comparable sensitivity of HSC detection as evaluated by limiting dilution analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018389

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  Versatile humanized niche model enables study of normal and malignant human hematopoiesis.

Authors:  Ander Abarrategi; Katie Foster; Ashley Hamilton; Syed A Mian; Diana Passaro; John Gribben; Ghulam Mufti; Dominique Bonnet
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

2.  Neuroblastoma cells negative for CD44 possess tumor-initiating properties.

Authors:  Elena K Siapati; Erasmia Rouka; Despina Kyriakou; George Vassilopoulos
Journal:  Cell Oncol (Dordr)       Date:  2011-03-22       Impact factor: 6.730

3.  Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice.

Authors:  Jun Hayakawa; Matthew M Hsieh; Naoya Uchida; Oswald Phang; John F Tisdale
Journal:  Stem Cells       Date:  2009-01       Impact factor: 6.277

4.  Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.

Authors:  Qizhen Shi; Erin L Kuether; Yingyu Chen; Jocelyn A Schroeder; Scot A Fahs; Robert R Montgomery
Journal:  Blood       Date:  2013-11-22       Impact factor: 22.113

5.  Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation.

Authors:  Laura Garcia-Perez; Lieke van Roon; Marco W Schilham; Arjan C Lankester; Karin Pike-Overzet; Frank J T Staal
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

6.  Acellular bone marrow extracts significantly enhance engraftment levels of human hematopoietic stem cells in mouse xeno-transplantation models.

Authors:  Kazem Zibara; Rima Hamdan; Leila Dib; Steen Sindet-Pedersen; Mohamed Kharfan-Dabaja; Ali Bazarbachi; Marwan El-Sabban
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

7.  A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia.

Authors:  E Saland; H Boutzen; R Castellano; L Pouyet; E Griessinger; C Larrue; F de Toni; S Scotland; M David; G Danet-Desnoyers; F Vergez; Y Barreira; Y Collette; C Récher; J-E Sarry
Journal:  Blood Cancer J       Date:  2015-03-20       Impact factor: 11.037

8.  Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia.

Authors:  Juan José Fung; Alan Kosaka; Xiaochuan Shan; Gwenn Danet-Desnoyers; Michael Gormally; Kate Owen
Journal:  Elife       Date:  2015-09-01       Impact factor: 8.140

Review 9.  Mouse models with human immunity and their application in biomedical research.

Authors:  Baojun Zhang; Ziyuan Duan; Yong Zhao
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

10.  Busulfan administration flexibility increases the applicability of scid repopulating cell assay in NSG mouse model.

Authors:  Jean Chevaleyre; Pascale Duchez; Laura Rodriguez; Marija Vlaski; Arnaud Villacreces; Véronique Conrad-Lapostolle; Vincent Praloran; Zoran Ivanovic; Philippe Brunet de la Grange
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.